Tag Archive for: cancer immunotherapy
Phase 1 Trial of a Triple Combination: 177Lu-PSMA-I&T, Olaparib, and Pembrolizumab
/in Clinical Trial, Metastatic, Phase 1/by MaxAI Platform Aims to Revolutionize Cancer Immunotherapy
/in Artificial Intelligence, Immunotherapy, Preclinical Research/by MaxA new AI platform developed by researchers at the Technical University of Denmark and the Scripps Research Institute has dramatically accelerated the design of specialized protein molecules called “minibinders” to enhance cancer immunotherapy. Normally, T cells recognize cancer cells by detecting protein fragments (peptides) presented on their surface by molecules known as pMHCs, but harnessing […]
New Immunotherapy Strategy Aims to Turn All Solid Tumors Into Immune Targets
/in Immunotherapy, Preclinical Research/by MaxBreakthrough in Cancer Immunotherapy: In Situ CAR-T Cell Generation Offers Hope for Lymphoma and Beyond
/in Immunotherapy, mRNA, Preclinical Research/by MaxA groundbreaking study led by Stanford Medicine, published in Cancer Immunology Research, has introduced a revolutionary approach to generating chimeric antigen receptor (CAR)-T cells directly inside the body, offering a promising new avenue for cancer treatment. This “in situ” method, which uses mRNA delivered via lipid nanoparticles (LNPs), successfully treated B-cell lymphoma in mice and […]
MDNA113 a Potentially Groundbreaking Immune Therapy for Solid Tumors Including mCRPC
/in Immunotherapy, Preclinical Research/by MaxPhase 2 Trial: ZG006 a New Immunotherapy for Neuroendocrine Prostate Cancer
/in Clinical Trial, Metastatic, Phase 2/by MaxPhase 1 Trial for DR-0202 Bispecific Antibody for Solid Tumors
/in Clinical Trial, Metastatic, Phase 1/by MaxPositive Results From Phase 3 Trial of CAN-2409 for Localized Prostate Cancer Led to RMAT Designation
/in Clinical Trial, Non-Metastatic, Phase 3/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- Organoids from Routine TUR‑P Samples: A Personalized Platform for Prostate Cancer Therapy Testing March 13, 2026
- Estrogen‑Based Androgen Suppression Plus ARSI in Prostate Cancer: A Phase 2 Quality‑of‑Life Trial March 13, 2026
- GLR2037: A First‑in‑Human AR‑Targeted PROTAC Enters Phase 1 Trials in Advanced Prostate Cancer March 13, 2026
- Durable PSA Control After Testosterone Recovery in High‑Risk Biochemical Recurrent Prostate Cancer March 13, 2026